Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Nadia Harbeck, Priya Rastogi, Miguel Martín, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1571-1581
Open Access | Times Cited: 308

Showing 1-25 of 308 citing articles:

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy, et al.
The Lancet Oncology (2022) Vol. 24, Iss. 1, pp. 77-90
Closed Access | Times Cited: 344
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Charles E. Geyer, Judy E. Garber, Richard D. Gelber, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1250-1268
Open Access | Times Cited: 278
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
Fabrice André, Nofisat Ismaila, Kimberly H. Allison, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 16, pp. 1816-1837
Open Access | Times Cited: 254
Breast cancer: an up‐to‐date review and future perspectives
Ruoxi Hong, Binghe Xu
Cancer Communications (2022) Vol. 42, Iss. 10, pp. 913-936
Open Access | Times Cited: 191
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Michael Gnant, Amylou C. Dueck, Sophie Frantal, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 3, pp. 282-293
Open Access | Times Cited: 169
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Dennis J. Slamon, O. N. Lipatov, Zbigniew Nowecki, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 12, pp. 1080-1091
Closed Access | Times Cited: 122
Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 112
ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
Shani Paluch‐Shimon, Fátima Cardoso, Ann H. Partridge, et al.
Annals of Oncology (2022) Vol. 33, Iss. 11, pp. 1097-1118
Open Access | Times Cited: 108
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
Kevin Kalinsky, Melissa Accordino, Codruța Chiuzan, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 24, pp. 4004-4013
Closed Access | Times Cited: 103
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani, Barbara Walley, Gini F. Fleming, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 7, pp. 1376-1382
Open Access | Times Cited: 92
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Laura A. Huppert, Özge Gümüşay, Damé Idossa, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 73, Iss. 5, pp. 480-515
Open Access | Times Cited: 88
Overview and countermeasures of cancer burden in China
Yian Wang, Qijia Yan, Chunmei Fan, et al.
Science China Life Sciences (2023) Vol. 66, Iss. 11, pp. 2515-2526
Open Access | Times Cited: 79
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
Hope S. Rugo, Joyce O’Shaughnessy, F Boyle, et al.
Annals of Oncology (2022) Vol. 33, Iss. 6, pp. 616-627
Open Access | Times Cited: 74
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022
Nina Ditsch, Achim Wöcke, Michael Untch, et al.
Breast Care (2022) Vol. 17, Iss. 4, pp. 403-420
Open Access | Times Cited: 72
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
Melanie Royce, Christy L. Osgood, Flora Mulkey, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 11, pp. 1155-1162
Open Access | Times Cited: 70
An emerging generation of endocrine therapies in breast cancer: a clinical perspective
Rima Patel, Paula Klein, Amy Tiersten, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 68
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
Dennis J. Slamon, Peter A. Fasching, Sara A. Hurvitz, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 63
Artificial Intelligence in Breast Cancer Diagnosis and Personalized Medicine
Jong Seok Ahn, Sangwon Shin, Su‐A Yang, et al.
Journal of Breast Cancer (2023) Vol. 26, Iss. 5, pp. 405-405
Open Access | Times Cited: 50
AI improves accuracy, agreement and efficiency of pathologists for Ki67 assessments in breast cancer
Amanda Dy, Ngoc-Nhu Jennifer Nguyen, Julien Meyer, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 15
Clinical Implications of Breast Cancer Intrinsic Subtypes
Alejandro Ríos-Hoyo, Naing-Lin Shan, Philipp L Karn, et al.
Advances in experimental medicine and biology (2025), pp. 435-448
Closed Access | Times Cited: 2
Therapeutic vaccines for breast cancer: Has the time finally come?
Chiara Corti, Pier Paolo Maria Berton Giachetti, Alexander M.M. Eggermont, et al.
European Journal of Cancer (2021) Vol. 160, pp. 150-174
Open Access | Times Cited: 63
Update on prognostic and predictive biomarkers of breast cancer
Yanjun Hou, Yan Peng, Zaibo Li
Seminars in Diagnostic Pathology (2022) Vol. 39, Iss. 5, pp. 322-332
Closed Access | Times Cited: 44
Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics
David R. Nelson, Jacqueline Brown, Aki Morikawa, et al.
PLoS ONE (2022) Vol. 17, Iss. 2, pp. e0264637-e0264637
Open Access | Times Cited: 41
Treatment of Breast Cancer in Young Adults
Megan E. Tesch, Ann H. Partridge
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 795-806
Closed Access | Times Cited: 38
The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations
Brian S. Finkelman, Huina Zhang, David G. Hicks, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 808-808
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top